DK0828851T3 - Tripeptidylpeptidaseinhibitorer - Google Patents

Tripeptidylpeptidaseinhibitorer

Info

Publication number
DK0828851T3
DK0828851T3 DK96916181T DK96916181T DK0828851T3 DK 0828851 T3 DK0828851 T3 DK 0828851T3 DK 96916181 T DK96916181 T DK 96916181T DK 96916181 T DK96916181 T DK 96916181T DK 0828851 T3 DK0828851 T3 DK 0828851T3
Authority
DK
Denmark
Prior art keywords
tripeptidyl peptidase
peptidase inhibitors
inhibitors
tripeptidyl
formulawherein
Prior art date
Application number
DK96916181T
Other languages
English (en)
Inventor
Jean-Charles Schwartz
Bertrand Leblond
Christiane Rose
Froylan Vargas
Pierre Bourgeat
Paul Beaumont Bishop
Ramesh Babarao Bambal
Charon Robin Ganellin
Andrew N J Moore
Suzanne Chan
Zhao Lihua
Original Assignee
Inst Nat Sante Rech Med
Bioprojet Soc Civ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Bioprojet Soc Civ filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of DK0828851T3 publication Critical patent/DK0828851T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/595—Gastrins; Cholecystokinins [CCK]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
DK96916181T 1995-05-09 1996-05-09 Tripeptidylpeptidaseinhibitorer DK0828851T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9505489A FR2733995B1 (fr) 1995-05-09 1995-05-09 Inhibiteurs de l'inactivation de neuropeptides endogenes notamment la cholecystokinine, leurs procedes de preparation leur utilisation comme medicaments et procede de criblage de medicaments
PCT/FR1996/000700 WO1996035805A2 (fr) 1995-05-09 1996-05-09 Inhibiteurs de tripeptidylpeptidases

Publications (1)

Publication Number Publication Date
DK0828851T3 true DK0828851T3 (da) 2005-10-24

Family

ID=9478806

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96916181T DK0828851T3 (da) 1995-05-09 1996-05-09 Tripeptidylpeptidaseinhibitorer

Country Status (11)

Country Link
US (2) US6403561B1 (da)
EP (1) EP0828851B1 (da)
JP (1) JPH11510684A (da)
AT (1) ATE299948T1 (da)
CA (1) CA2221035A1 (da)
DE (1) DE69634955T2 (da)
DK (1) DK0828851T3 (da)
ES (1) ES2244969T3 (da)
FR (1) FR2733995B1 (da)
PT (1) PT828851E (da)
WO (1) WO1996035805A2 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2733995B1 (fr) * 1995-05-09 1997-07-25 Inst Nat Sante Rech Med Inhibiteurs de l'inactivation de neuropeptides endogenes notamment la cholecystokinine, leurs procedes de preparation leur utilisation comme medicaments et procede de criblage de medicaments
DE69838686T2 (de) * 1997-12-23 2008-08-28 Institut National De La Santé Et De La Recherche Médicale (Inserm) Tripeptidylpeptidaseinhibitoren
DE60045474D1 (de) 1999-01-13 2011-02-17 Univ New York State Res Found Neues verfahren zum erschaffen von proteinkinase-inhibitoren
WO2001081306A2 (en) * 2000-04-19 2001-11-01 Eli Lilly And Company Azide cyclization-based synthesis and intermediates for spla2 inhibitors
DK1392291T3 (da) 2000-10-30 2007-10-08 Janssen Pharmaceutica Nv Tripeptidylpeptidaseinhibitorer
JP4623962B2 (ja) * 2001-10-22 2011-02-02 ザ・リサーチ・ファウンデーション・オブ・ステイト・ユニバーシティ・オブ・ニューヨーク タンパク質キナーゼおよびホスファターゼ阻害剤、それらを設計する方法、ならびにそれらを使用する方法
US7005445B2 (en) 2001-10-22 2006-02-28 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
US20030165574A1 (en) * 2002-03-01 2003-09-04 Ward Loren Spencer Compositions and methods for treatment of body weight conditions
US20040097422A1 (en) * 2002-06-14 2004-05-20 Karl Munger Methods of use for tripeptidyl peptidase II inhibitors as anticancer agents
US7838542B2 (en) 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
CN104736519B (zh) 2012-10-11 2018-12-04 霍夫曼-拉罗奇有限公司 吲哚啉类

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH626872A5 (da) * 1976-06-21 1981-12-15 Hoffmann La Roche
PH14141A (en) * 1976-06-25 1981-03-05 Hoffmann La Roche Pharmaceutical composition containing dipeptide derivatives
HU180925B (en) * 1979-06-28 1983-05-30 Richter Gedeon Vegyeszet Process for producing tripeptide-amides trh-analogues,effectives on the central nerve systhem
CS226907B1 (en) * 1981-08-07 1984-04-16 Kasafirek Evzen Alkylamides of carboxyalkanoylpeptides
AT389517B (de) * 1987-10-08 1989-12-27 Hoechst Ag Chromophore peptide, verfahren zu ihrer herstellung und ihre verwendung zum nachweis der peptidylglycin-alpha-amidierenden monooxygenase
US5159060A (en) * 1988-05-27 1992-10-27 Mayo Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
DE69231674T2 (de) * 1991-10-22 2001-08-09 New England Medical Center Inc Inhibitoren der dipeptidyl-aminopeptidase vom typ-iv
FR2733995B1 (fr) * 1995-05-09 1997-07-25 Inst Nat Sante Rech Med Inhibiteurs de l'inactivation de neuropeptides endogenes notamment la cholecystokinine, leurs procedes de preparation leur utilisation comme medicaments et procede de criblage de medicaments

Also Published As

Publication number Publication date
US6403561B1 (en) 2002-06-11
EP0828851B1 (fr) 2005-07-20
CA2221035A1 (fr) 1996-11-14
DE69634955T2 (de) 2006-05-24
WO1996035805A3 (fr) 1997-01-30
US20030027743A1 (en) 2003-02-06
ATE299948T1 (de) 2005-08-15
JPH11510684A (ja) 1999-09-21
ES2244969T3 (es) 2005-12-16
EP0828851A2 (fr) 1998-03-18
FR2733995A1 (fr) 1996-11-15
PT828851E (pt) 2005-11-30
FR2733995B1 (fr) 1997-07-25
DE69634955D1 (de) 2005-08-25
WO1996035805A2 (fr) 1996-11-14

Similar Documents

Publication Publication Date Title
AU7321598A (en) Use of cholinesterase inhibitors to treat disorders of attention
EA199800667A1 (ru) Новые фенантридины
MX9302011A (es) Derivados de indol.
IS4955A (is) Tálmar gegn frumusamloðun
ATE250576T1 (de) Substituierte pyrrolylverbindungen zur behandlung von entzündungen
ES2067945T3 (es) Derivados de hidroxiurea hipoglicemica.
TR200000374T2 (tr) Akut akciğer harabiyeti ve fibrozitinin alfavbeta6 antagonistleriyle tedavisi.
BG102918A (en) Biphenylsulphanomide inhibitors of the matrix metalloproteinase
DK0828851T3 (da) Tripeptidylpeptidaseinhibitorer
UA66793C2 (uk) Лептин як стримувач швидкого збільшення пухлини клітини
NO982778D0 (no) Morfinderivater med smertestillende virkning
MX9702035A (es) Inhibidores de 5-alfa reductasa.
TR199801665T2 (xx) Makular �demin engellenmesi i�in karbonik anhidraz inhibit�rlerinin kullan�m�.
GB2324091B (en) Metalloproteinase inhibitors
NO965497L (no) Fremgangsmåte for kontrollert fiksering av avleiringsinhibitor i en underjordisk formasjon
ES2285735T3 (es) Modelo molecular para inhibidores de vla-4.
ES2060405T3 (es) Derivado de la melatonina que tiene actividad terapeutica en dermatologia.
EE9700350A (et) COMT-inhibiitorite uus kasutamine ja diabeetiliste vaskulaarsete häirete ärahoidmise meetod
EA199900174A1 (ru) Способ лечения биполярного расстройства
ATE270113T1 (de) Zusammenstellungen zur verbesserten wundheilung
ATE306269T1 (de) Behandlung der exzessiven aggressivität mit olanzapine
AR005866A1 (es) Composicion farmaceutica antioxidante
TR199701613T1 (xx) Selim prostatik hiperplasyan�n tedavisi i�in melatonin agonistleri.
PT937075E (pt) Novas imidazo- e oxazolo-piridinas como inibidores da fosfodiesterese
ATE131509T1 (de) Calciumborat/aminocarboxylat- korrosionsinhibitoren